Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 220 entries
Sorted by: Best Match Show Resources per page
Collision of Trapped Topoisomerase 2 with Transcription and Replication: Generation and Repair of DNA Double-Strand Breaks with 5' Adducts.

Genes

Yan H, Tammaro M, Liao S.
PMID: 27376333
Genes (Basel). 2016 Jul 01;7(7). doi: 10.3390/genes7070032.

Topoisomerase 2 (Top2) is an essential enzyme responsible for manipulating DNA topology during replication, transcription, chromosome organization and chromosome segregation. It acts by nicking both strands of DNA and then passes another DNA molecule through the break. The 5'...

Cite
Yan H, Tammaro M, Liao S. Collision of Trapped Topoisomerase 2 with Transcription and Replication: Generation and Repair of DNA Double-Strand Breaks with 5' Adducts. Genes (Basel). 2016;7(7)doi: 10.3390/genes7070032.
Yan, H., Tammaro, M., & Liao, S. (2016). Collision of Trapped Topoisomerase 2 with Transcription and Replication: Generation and Repair of DNA Double-Strand Breaks with 5' Adducts. Genes, 7(7), . https://doi.org/10.3390/genes7070032
Yan, Hong, et al. "Collision of Trapped Topoisomerase 2 with Transcription and Replication: Generation and Repair of DNA Double-Strand Breaks with 5' Adducts." Genes vol. 7,7 (2016). doi: https://doi.org/10.3390/genes7070032
Yan H, Tammaro M, Liao S. Collision of Trapped Topoisomerase 2 with Transcription and Replication: Generation and Repair of DNA Double-Strand Breaks with 5' Adducts. Genes (Basel). 2016 Jul 01;7(7). doi: 10.3390/genes7070032. PMID: 27376333; PMCID: PMC4962002.
Copy Download .nbib Format: NLM
Regulation of H-Ras-driven MAPK signaling, transformation and tumorigenesis, but not PI3K signaling and tumor progression, by plasma membrane microdomains.

Oncogenesis

Michael JV, Wurtzel JG, Goldfinger LE.
PMID: 27239960
Oncogenesis. 2016 May 30;5(5):e228. doi: 10.1038/oncsis.2016.36.

In this study, we assessed the contributions of plasma membrane (PM) microdomain targeting to the functions of H-Ras and R-Ras. These paralogs have identical effector-binding regions, but variant C-terminal targeting domains (tDs) which are responsible for lateral microdomain distribution:...

Cite
Michael JV, Wurtzel JG, Goldfinger LE. Regulation of H-Ras-driven MAPK signaling, transformation and tumorigenesis, but not PI3K signaling and tumor progression, by plasma membrane microdomains. Oncogenesis. 2016;5(5):e228doi: 10.1038/oncsis.2016.36.
Michael, J. V., Wurtzel, J. G., & Goldfinger, L. E. (2016). Regulation of H-Ras-driven MAPK signaling, transformation and tumorigenesis, but not PI3K signaling and tumor progression, by plasma membrane microdomains. Oncogenesis, 5(5), e228. https://doi.org/10.1038/oncsis.2016.36
Michael, J V, et al. "Regulation of H-Ras-driven MAPK signaling, transformation and tumorigenesis, but not PI3K signaling and tumor progression, by plasma membrane microdomains." Oncogenesis vol. 5,5 (2016): e228. doi: https://doi.org/10.1038/oncsis.2016.36
Michael JV, Wurtzel JG, Goldfinger LE. Regulation of H-Ras-driven MAPK signaling, transformation and tumorigenesis, but not PI3K signaling and tumor progression, by plasma membrane microdomains. Oncogenesis. 2016 May 30;5(5):e228. doi: 10.1038/oncsis.2016.36. PMID: 27239960; PMCID: PMC4945753.
Copy Download .nbib Format: NLM
Development and utilization of complementary communication channels for treatment decision making and survivorship issues among cancer patients: The CIS Research Consortium Experience.

Internet interventions

Fleisher L, Wen KY, Miller SM, Diefenbach M, Stanton AL, Ropka M, Morra M, Raich PC.
PMID: 26855885
Internet Interv. 2015 Nov 01;2(4):392-398. doi: 10.1016/j.invent.2015.09.002.

OBJECTIVE: Cancer patients and survivors are assuming active roles in decision-making and digital patient support tools are widely used to facilitate patient engagement. As part of Cancer Information Service Research Consortium's randomized controlled trials focused on the efficacy of...

Cite
Fleisher L, Wen KY, Miller SM, et al. Development and utilization of complementary communication channels for treatment decision making and survivorship issues among cancer patients: The CIS Research Consortium Experience. Internet Interv. 2015;2(4):392-398doi: 10.1016/j.invent.2015.09.002.
Fleisher, L., Wen, K. Y., Miller, S. M., Diefenbach, M., Stanton, A. L., Ropka, M., Morra, M., & Raich, P. C. (2015). Development and utilization of complementary communication channels for treatment decision making and survivorship issues among cancer patients: The CIS Research Consortium Experience. Internet interventions, 2(4), 392-398. https://doi.org/10.1016/j.invent.2015.09.002
Fleisher, Linda, et al. "Development and utilization of complementary communication channels for treatment decision making and survivorship issues among cancer patients: The CIS Research Consortium Experience." Internet interventions vol. 2,4 (2015): 392-398. doi: https://doi.org/10.1016/j.invent.2015.09.002
Fleisher L, Wen KY, Miller SM, Diefenbach M, Stanton AL, Ropka M, Morra M, Raich PC. Development and utilization of complementary communication channels for treatment decision making and survivorship issues among cancer patients: The CIS Research Consortium Experience. Internet Interv. 2015 Nov 01;2(4):392-398. doi: 10.1016/j.invent.2015.09.002. PMID: 26855885; PMCID: PMC4740910.
Copy Download .nbib Format: NLM
Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab.

Journal for immunotherapy of cancer

Zibelman M, Pollak N, Olszanski AJ.
PMID: 26885370
J Immunother Cancer. 2016 Feb 16;4:8. doi: 10.1186/s40425-016-0114-4. eCollection 2016.

BACKGROUND: Immune related adverse events affecting various organ systems are a recognized potential consequence of immune checkpoint inhibition. However, autoimmune inner ear disease is one complication not previously associated with the use of checkpoint inhibitors, though it has been...

Cite
Zibelman M, Pollak N, Olszanski AJ. Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. J Immunother Cancer. 2016;4:8doi: 10.1186/s40425-016-0114-4.
Zibelman, M., Pollak, N., & Olszanski, A. J. (2016). Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. Journal for immunotherapy of cancer, 48. https://doi.org/10.1186/s40425-016-0114-4
Zibelman, Matthew, et al. "Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab." Journal for immunotherapy of cancer vol. 4 (2016): 8. doi: https://doi.org/10.1186/s40425-016-0114-4
Zibelman M, Pollak N, Olszanski AJ. Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. J Immunother Cancer. 2016 Feb 16;4:8. doi: 10.1186/s40425-016-0114-4. eCollection 2016. PMID: 26885370; PMCID: PMC4754989.
Copy Download .nbib Format: NLM
Retroviral DNA Transposition: Themes and Variations.

Microbiology spectrum

Skalka AM.
PMID: 25844274
Microbiol Spectr. 2014 Dec;2(5):MDNA300052014. doi: 10.1128/microbiolspec.MDNA3-0005-2014.

Retroviruses and LTR retrotransposons are transposable elements that encapsidate the RNAs that are intermediates in the transposition of DNA copies of their genomes (proviruses), from one cell (or one locus) to another. Mechanistic similarities in DNA transposase enzymes and...

Cite
Skalka AM. Retroviral DNA Transposition: Themes and Variations. Microbiol Spectr. 2014;2(5):MDNA300052014doi: 10.1128/microbiolspec.MDNA3-0005-2014.
Skalka, A. M. (2014). Retroviral DNA Transposition: Themes and Variations. Microbiology spectrum, 2(5), MDNA300052014. https://doi.org/10.1128/microbiolspec.MDNA3-0005-2014
Skalka, Anna Marie. "Retroviral DNA Transposition: Themes and Variations." Microbiology spectrum vol. 2,5 (2014): MDNA300052014. doi: https://doi.org/10.1128/microbiolspec.MDNA3-0005-2014
Skalka AM. Retroviral DNA Transposition: Themes and Variations. Microbiol Spectr. 2014 Dec;2(5):MDNA300052014. doi: 10.1128/microbiolspec.MDNA3-0005-2014. PMID: 25844274; PMCID: PMC4383315.
Copy Download .nbib Format: NLM
Pseudomonas aeruginosa porphobilinogen synthase assembly state regulators: hit discovery and initial SAR studies.

ARKIVOC : free online journal of organic chemistry

Reitz AB, Ramirez UD, Stith L, Du Y, Smith GR, Jaffe EK.
PMID: 21643541
ARKIVOC. 2010 Jun;2010:175-188.

Porphobilinogen synthase (PBGS) catalyzes the first common step in the biosynthesis of the essential heme, chlorophyll and vitamin B(12) heme pigments. PBGS activity is regulated by assembly state, with certain oligomers exhibiting biological activity and others either partially or...

Cite
Reitz AB, Ramirez UD, Stith L, et al. Pseudomonas aeruginosa porphobilinogen synthase assembly state regulators: hit discovery and initial SAR studies. ARKIVOC. 2010;2010:175-188
Reitz, A. B., Ramirez, U. D., Stith, L., Du, Y., Smith, G. R., & Jaffe, E. K. (2010). Pseudomonas aeruginosa porphobilinogen synthase assembly state regulators: hit discovery and initial SAR studies. ARKIVOC : free online journal of organic chemistry, 2010175-188.
Reitz, Allen B, et al. "Pseudomonas aeruginosa porphobilinogen synthase assembly state regulators: hit discovery and initial SAR studies." ARKIVOC : free online journal of organic chemistry vol. 2010 (2010): 175-188.
Reitz AB, Ramirez UD, Stith L, Du Y, Smith GR, Jaffe EK. Pseudomonas aeruginosa porphobilinogen synthase assembly state regulators: hit discovery and initial SAR studies. ARKIVOC. 2010 Jun;2010:175-188. PMID: 21643541; PMCID: PMC3106444.
Copy Download .nbib Format: NLM
Evidence for DNA damage checkpoint activation in barrett esophagus.

Translational oncology

von Holzen U, Chen T, Boquoi A, Richter JE, Falk GW, Klein-Szanto AJ, Cooper H, Litwin S, Weinberg DS, Enders GH.
PMID: 20165693
Transl Oncol. 2010 Feb;3(1):33-42. doi: 10.1593/tlo.09187.

Barrett esophagus is an epithelial metaplasia that predisposes to adenocarcinoma. Better markers of cancer risk are urgently needed to identify those patients who are likely to benefit most from emerging methods of endoscopic ablation. Disease progression is associated with...

Cite
von Holzen U, Chen T, Boquoi A, et al. Evidence for DNA damage checkpoint activation in barrett esophagus. Transl Oncol. 2010;3(1):33-42doi: 10.1593/tlo.09187.
von Holzen, U., Chen, T., Boquoi, A., Richter, J. E., Falk, G. W., Klein-Szanto, A. J., Cooper, H., Litwin, S., Weinberg, D. S., & Enders, G. H. (2010). Evidence for DNA damage checkpoint activation in barrett esophagus. Translational oncology, 3(1), 33-42. https://doi.org/10.1593/tlo.09187
von Holzen, Urs, et al. "Evidence for DNA damage checkpoint activation in barrett esophagus." Translational oncology vol. 3,1 (2010): 33-42. doi: https://doi.org/10.1593/tlo.09187
von Holzen U, Chen T, Boquoi A, Richter JE, Falk GW, Klein-Szanto AJ, Cooper H, Litwin S, Weinberg DS, Enders GH. Evidence for DNA damage checkpoint activation in barrett esophagus. Transl Oncol. 2010 Feb;3(1):33-42. doi: 10.1593/tlo.09187. PMID: 20165693; PMCID: PMC2822452.
Copy Download .nbib Format: NLM
A semi-parametric generalization of the Cox proportional hazards regression model: Inference and Applications.

Computational statistics & data analysis

Devarajan K, Ebrahimi N.
PMID: 21076652
Comput Stat Data Anal. 2011 Jan 01;55(1):667-676. doi: 10.1016/j.csda.2010.06.010.

The assumption of proportional hazards (PH) fundamental to the Cox PH model sometimes may not hold in practice. In this paper, we propose a generalization of the Cox PH model in terms of the cumulative hazard function taking a...

Cite
Devarajan K, Ebrahimi N. A semi-parametric generalization of the Cox proportional hazards regression model: Inference and Applications. Comput Stat Data Anal. 2011;55(1):667-676doi: 10.1016/j.csda.2010.06.010.
Devarajan, K., & Ebrahimi, N. (2011). A semi-parametric generalization of the Cox proportional hazards regression model: Inference and Applications. Computational statistics & data analysis, 55(1), 667-676. https://doi.org/10.1016/j.csda.2010.06.010
Devarajan, Karthik, and Ebrahimi, Nader. "A semi-parametric generalization of the Cox proportional hazards regression model: Inference and Applications." Computational statistics & data analysis vol. 55,1 (2011): 667-676. doi: https://doi.org/10.1016/j.csda.2010.06.010
Devarajan K, Ebrahimi N. A semi-parametric generalization of the Cox proportional hazards regression model: Inference and Applications. Comput Stat Data Anal. 2011 Jan 01;55(1):667-676. doi: 10.1016/j.csda.2010.06.010. PMID: 21076652; PMCID: PMC2976538.
Copy Download .nbib Format: NLM
Pilot study: health behaviors associated with human papillomavirus vaccine acceptance among adolescents.

Journal of primary care & community health

Heckman CJ, Fang CY, Jayo I.
PMID: 23803777
J Prim Care Community Health. 2012 Jul 01;3(3):170-3. doi: 10.1177/2150131911429574. Epub 2012 Jan 06.

BACKGROUND: Despite approval of a vaccine found to be very effective in preventing human papillomavirus infection and related cancers, many young people have not yet been vaccinated. Because health behaviors tend to co-occur, the purpose of the current study...

Cite
Heckman CJ, Fang CY, Jayo I. Pilot study: health behaviors associated with human papillomavirus vaccine acceptance among adolescents. J Prim Care Community Health. 2012;3(3):170-3doi: 10.1177/2150131911429574.
Heckman, C. J., Fang, C. Y., & Jayo, I. (2012). Pilot study: health behaviors associated with human papillomavirus vaccine acceptance among adolescents. Journal of primary care & community health, 3(3), 170-3. https://doi.org/10.1177/2150131911429574
Heckman, Carolyn J, et al. "Pilot study: health behaviors associated with human papillomavirus vaccine acceptance among adolescents." Journal of primary care & community health vol. 3,3 (2012): 170-3. doi: https://doi.org/10.1177/2150131911429574
Heckman CJ, Fang CY, Jayo I. Pilot study: health behaviors associated with human papillomavirus vaccine acceptance among adolescents. J Prim Care Community Health. 2012 Jul 01;3(3):170-3. doi: 10.1177/2150131911429574. Epub 2012 Jan 06. PMID: 23803777; PMCID: PMC3695443.
Copy Download .nbib Format: NLM
EVALUATING COSTS WITH UNMEASURED CONFOUNDING: A SENSITIVITY ANALYSIS FOR THE TREATMENT EFFECT.

The annals of applied statistics

Handorf EA, Bekelman JE, Heitjan DF, Mitra N.
PMID: 24587844
Ann Appl Stat. 2013;7(4):2062-2080. doi: 10.1214/13-AOAS665.

Estimates of the effects of treatment on cost from observational studies are subject to bias if there are unmeasured confounders. It is therefore advisable in practice to assess the potential magnitude of such biases. We derive a general adjustment...

Cite
Handorf EA, Bekelman JE, Heitjan DF, et al. EVALUATING COSTS WITH UNMEASURED CONFOUNDING: A SENSITIVITY ANALYSIS FOR THE TREATMENT EFFECT. Ann Appl Stat. 2013;7(4):2062-2080doi: 10.1214/13-AOAS665.
Handorf, E. A., Bekelman, J. E., Heitjan, D. F., & Mitra, N. (2013). EVALUATING COSTS WITH UNMEASURED CONFOUNDING: A SENSITIVITY ANALYSIS FOR THE TREATMENT EFFECT. The annals of applied statistics, 7(4), 2062-2080. https://doi.org/10.1214/13-AOAS665
Handorf, Elizabeth A, et al. "EVALUATING COSTS WITH UNMEASURED CONFOUNDING: A SENSITIVITY ANALYSIS FOR THE TREATMENT EFFECT." The annals of applied statistics vol. 7,4 (2013): 2062-2080. doi: https://doi.org/10.1214/13-AOAS665
Handorf EA, Bekelman JE, Heitjan DF, Mitra N. EVALUATING COSTS WITH UNMEASURED CONFOUNDING: A SENSITIVITY ANALYSIS FOR THE TREATMENT EFFECT. Ann Appl Stat. 2013;7(4):2062-2080. doi: 10.1214/13-AOAS665. PMID: 24587844; PMCID: PMC3935434.
Copy Download .nbib Format: NLM
A Hybrid Algorithm for Non-negative Matrix Factorization Based on Symmetric Information Divergence.

Proceedings. IEEE International Conference on Bioinformatics and Biomedicine

Devarajan K, Ebrahimi N, Soofi E.
PMID: 28868206
Proceedings (IEEE Int Conf Bioinformatics Biomed). 2015 Nov;2015:1658-1664. doi: 10.1109/BIBM.2015.7359924. Epub 2015 Dec 17.

The objective of this paper is to provide a hybrid algorithm for non-negative matrix factorization based on a symmetric version of Kullback-Leibler divergence, known as

Cite
Devarajan K, Ebrahimi N, Soofi E. A Hybrid Algorithm for Non-negative Matrix Factorization Based on Symmetric Information Divergence. Proceedings (IEEE Int Conf Bioinformatics Biomed). 2015;2015:1658-1664doi: 10.1109/BIBM.2015.7359924.
Devarajan, K., Ebrahimi, N., & Soofi, E. (2015). A Hybrid Algorithm for Non-negative Matrix Factorization Based on Symmetric Information Divergence. Proceedings. IEEE International Conference on Bioinformatics and Biomedicine, 20151658-1664. https://doi.org/10.1109/BIBM.2015.7359924
Devarajan, Karthik, et al. "A Hybrid Algorithm for Non-negative Matrix Factorization Based on Symmetric Information Divergence." Proceedings. IEEE International Conference on Bioinformatics and Biomedicine vol. 2015 (2015): 1658-1664. doi: https://doi.org/10.1109/BIBM.2015.7359924
Devarajan K, Ebrahimi N, Soofi E. A Hybrid Algorithm for Non-negative Matrix Factorization Based on Symmetric Information Divergence. Proceedings (IEEE Int Conf Bioinformatics Biomed). 2015 Nov;2015:1658-1664. doi: 10.1109/BIBM.2015.7359924. Epub 2015 Dec 17. PMID: 28868206; PMCID: PMC5577987.
Copy Download .nbib Format: NLM
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial.

European urology oncology

Anari F, O'Neill J, Choi W, Chen DYT, Haseebuddin M, Kutikov A, Dulaimi E, Alpaugh RK, Devarajan K, Greenberg RE, Bilusic M, Wong YN, Viterbo R, Hoffman-Censits JH, Lallas CD, Trabulsi EJ, Smaldone M, Geynisman DM, Zibelman M, Lin J, Kelly WK, Uzzo R, McConkey D, Plimack ER.
PMID: 30420974
Eur Urol Oncol. 2018 May;1(1):54-60. doi: 10.1016/j.euo.2018.02.007. Epub 2018 Jun 06.

BACKGROUND: Accelerated (also termed dose-dense, DD) chemotherapy regimens such as accelerated methotrexate, vinblastine, doxorubicin, and cisplatin have shown better efficacy and tolerability in the metastatic setting, and shortened the time to surgery in the neoadjuvant setting compared to standard-schedule...

Cite
Anari F, O'Neill J, Choi W, et al. Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol. 2018;1(1):54-60doi: 10.1016/j.euo.2018.02.007.
Anari, F., O'Neill, J., Choi, W., Chen, D. Y. T., Haseebuddin, M., Kutikov, A., Dulaimi, E., Alpaugh, R. K., Devarajan, K., Greenberg, R. E., Bilusic, M., Wong, Y. N., Viterbo, R., Hoffman-Censits, J. H., Lallas, C. D., Trabulsi, E. J., Smaldone, M., Geynisman, D. M., Zibelman, M., Lin, J., Kelly, W. K., Uzzo, R., McConkey, D., & Plimack, E. R. (2018). Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. European urology oncology, 1(1), 54-60. https://doi.org/10.1016/j.euo.2018.02.007
Anari, Fern, et al. "Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial." European urology oncology vol. 1,1 (2018): 54-60. doi: https://doi.org/10.1016/j.euo.2018.02.007
Anari F, O'Neill J, Choi W, Chen DYT, Haseebuddin M, Kutikov A, Dulaimi E, Alpaugh RK, Devarajan K, Greenberg RE, Bilusic M, Wong YN, Viterbo R, Hoffman-Censits JH, Lallas CD, Trabulsi EJ, Smaldone M, Geynisman DM, Zibelman M, Lin J, Kelly WK, Uzzo R, McConkey D, Plimack ER. Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol. 2018 May;1(1):54-60. doi: 10.1016/j.euo.2018.02.007. Epub 2018 Jun 06. PMID: 30420974; PMCID: PMC6226048.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 220 entries